Document is current

Article History

Received: 11 August 2025

Accepted: 11 December 2025

First Online: 17 December 2025

Declarations

:

: approval of the study by the Ethics Committee of the University Medical Center Göttingen was granted on January 05, 2022 (application number: 33/12/21). All patients gave their written informed consent for the study participation. All procedures were carried out in accordance with the ethical principles of the Declaration of Helsinki. The study was registered at the WHO-licensed German clinical trial registry (DRKS00033171).

: Not applicable.

: SG received speaker´s honoraria for lecturing from Argenx, Alexion and UCB and travel, accommodation and congress fees from Grifols, UCB and Alexion. SM received speaker´s honoraria for lecturing from Argenx, and travel, accommodation and congress fees from Biotest, Kedrion, Alnylam Pharmaceuticals, Argenx und Janssen. RZ has received honoraria from Argenx as well as travel expenses to attend congresses from Biogen, LFB, and Octapharma. AS has received honoraria from Argenx. KK received speaker´s honoraria for lecturing and travel, accommodation and congress fees from Argenx, Alexion and UCB. JZ received speaker´s honoraria for lecturing from: Alexion, Amicus, Argenx, Kedrion, Roche, Sanofi and UCB and travel, accommodation and congress fees from Alexion, Argenx, Janssen, Kedrion, Sanofi and UCB. Research was granted from Argenx and UCB. JZ is board member of the German Myasthenia Association and member of the German Muscle Society. JL, LH, DR, IH and TGV declare no competing interests.